<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        186-212-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARVIDOL 12.5 MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CARVEDILOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AG02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Carvidol is a medicinal product contains carvedilol as an active ingredient.<br />Carvedilol belongs to a group of medicines called beta-blockers that work by relaxing and<br />widening the blood vessels. This makes it easier for your heart to pump blood around the body<br />and reduces blood pressure and strain on your heart.<br />Carvidol is used: -<br />&bull; For the treatment of high blood pressure (hypertension),<br />&bull; For the treatment of chest pain that occurs when the arteries that supply your heart with blood<br />carrying oxygen are narrowed which results in less oxygen reaching your heart muscles<br />(angina),<br />&bull; For the treatment of weakening of the heart muscle (heart failure), in combination with other<br />medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DO NOT TAKE CARVIDOL:<br />&bull; If you are allergic (hypersensitive) to carvedilol or any of the other ingredients of Carvidol<br />(as listed in section 6 &#39;Further Information&#39;),<br />&bull; If you have a history of wheezing due to asthma or other lung diseases,<br />&bull; If you have been told you have very severe heart failure and you have fluid retention<br />(swelling) which is being treated with injections of medicines into your veins<br />(intravenously),<br />&bull; If you have liver disease,</p><p>&bull; If you have been told that you have a very slow heartbeat,<br />&bull; If you have very low blood pressure,<br />&bull; If you have been told you have a condition called Prinzmetal&#39;s angina,<br />&bull; If you have phaeochromocytoma (a tumour of the adrenal gland causing high blood pressure)<br />which is not being treated,<br />&bull; If you are suffering from serious disturbances in the body&#39;s acid-base balance (metabolic<br />acidosis),<br />&bull; If you have very poor blood circulation in the hands and feet resulting in coldness and pain in<br />them,<br />&bull; If you have a particular conduction defect of the heart (called an AV heart block Grade II or<br />III (unless a pacemaker is fitted) or a SA block),<br />&bull; If you are currently being treated with injections of verapamil or diltiazem (used in the<br />treatment of high blood pressure or heart problems).<br />If any of these apply to you, do not take Carvidol.<br />Warnings and precautions<br />It is important to tell your doctor before taking Carvidol if you:<br />&bull; Have been told you suffer from any other heart problems,<br />&bull; Have or have ever had any problems with your liver, kidneys or thyroid,<br />&bull; Have diabetes. Carvidol may hide your usual symptoms of low blood sugar,<br />&bull; Have a skin condition known as psoriasis,<br />&bull; Have poor circulation affecting hands, feet or lower legs, or Raynaud&#39;s phenomenon,<br />&bull; Have or have ever had a serious allergic reaction or you are undergoing allergic<br />desensitization therapy for any type of severe allergy,<br />&bull; Wear contact lenses because Carvidol may cause the eyes to be drier than normal.<br />Warnings:<br />Severe cutaneous adverse reactions (SCARs):<br />&bull; Very rare cases of severe cutaneous adverse reactions such as toxic epidermal necrolysis<br />(TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with<br />Carvidol [see section 4 (Possible side effects)].<br />Other medicines and Carvidol<br />Tell your doctor or pharmacist if you are taking or have recently taking, have recently taken or<br />might take any other medicines.<br />How to take Carvidol:<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription or herbal medicines. Take<br />particular care and tell your doctor or pharmacist, if you are taking any of the following<br />medicines:<br />&bull; Medicines used to treat an irregular heartbeat (e.g. diltiazem, verapamil or amiodarone),</p><p>&bull; Nitrate medicines for angina (e.g. isosorbide mononitrate or glyceryl trinitrate),<br />&bull; Medicines used to treat heart failure (e.g. Digoxin),<br />&bull; Any other medicine used to treat high blood pressure (e.g. doxazosin, reserpine, amlodipine<br />or indoramin),<br />&bull; Medicines used to treat depression or other mental health conditions (e.g. fluoxetine, tricyclic<br />antidepressants, barbiturates, phenothiazines, haloperidol or monoamine oxide inhibitors<br />(MAOls),<br />&bull; Medicines used to prevent your body rejecting organs after transplant operations (e.g.<br />ciclosporin),<br />&bull; Medicines to reduce blood sugar such as oral antidiabetic medicines or insulin,<br />&bull; Medicines used to reduce blood pressure or to treat migraine (e.g. clonidine or ergotamine),<br />&bull; Certain painkilling agents such as non-steroidal anti-inflammatory medicines (NSAIDs) (e.g.<br />ibuprofen or diclofenac),<br />&bull; Medicines used for hormone replacement therapy (e.g. estrogens),<br />&bull; Corticosteroids used to suppress inflammatory or allergic reactions (e.g. prednisolone),<br />&bull; Medicines used to treat bacterial infections (e.g. rifampicin or erythromycin),<br />&bull; Medicines used to treat stomach ulcers, heartburn and acid reflux (e.g. cimetidine),<br />&bull; Medicines used to treat fungal infections (e.g. ketoconazole),<br />&bull; Medicines sometimes used in decongestant cough and cold remedies (e.g. ephedrine or<br />pseudoephedrine).<br />If you need to have an anesthetic for an operation, tell your hospital doctor you are taking<br />Carvidol.<br />Taking Carvidol with food and drink<br />You should take Carvidol with water.<br />If you are taking Carvidol to treat heart failure, you should take this medicine with water at your<br />mealtime (see section 3 &#39;How to take Carvidol).<br />Do not drink alcohol whilst taking Carvidol as it might worsen the effects of alcohol.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, do not take this medicine until you have talked to your<br />doctor. Consult your doctor immediately if you become pregnant while taking this medicine.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />You may experience dizziness or tiredness whilst taking Carvidol. This is more likely to occur<br />when you first begin treatment, or when the dose is increased. If this occurs, you should not drive<br />or operate machinery. You should avoid drinking alcohol, as it may make these symptoms<br />worse. If you are concerned or want more information, you should talk to your doctor.<br />Important information about some ingredients of Carvidol<br />Carvidol contains lactose. If you have been told by your doctor that you have intolerance to some<br />sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Carvidol exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure.<br />Carvidol should be swallowed with a drink of water.<br />High blood pressure<br />Adults: The usual starting dose is 12.5 mg once a day for the first two days.<br />After this, the dose is increased to 25 mg once a day. If necessary, your doctor may gradually<br />increase the dose further at intervals of two weeks or more. The maximum recommended daily<br />dose is 50 mg (the maximum recommended single dose is 25 mg).<br />Elderly: Your doctor will usually start you on 12.5 mg once a day and continue with this dose for<br />the length of your treatment. If necessary, your doctor may increase your dose gradually at<br />intervals of two weeks or more.<br />Angina<br />Adults: The usual starting dose is 12.5 mg twice a day for the first two days.<br />After this, the dose is increased to 25 mg twice a day. If necessary, your doctor may gradually<br />increase the dose further at intervals of two weeks or more to a maximum of 100 mg a day in two<br />doses.<br />Elderly: The recommended starting dose is 12.5 mg twice a day for two days.<br />After this, the dose may be increased to 25 mg twice a day, which is the recommended maximum<br />daily dose.<br />Heart failure<br />Adults and elderly: For the treatment of stable heart failure, the tablets should be taken twice a<br />day, in the morning and in the evening, and should be taken with food in order to reduce the risk<br />of side effects.<br />The starting dose is 3.125 mg twice a day for two weeks. Your doctor will then gradually<br />increase the strength of tablets you take at intervals of two weeks or more until you receive the<br />dose that suits you best.<br />If you weigh less than 85 kg, the maximum recommended dose of Carvidol is 25 mg twice a day,<br />if you weigh more than 85 kg, your doctor may increase your dose to 50 mg twice a day.<br />For the treatment of heart failure, it is recommended that your treatment with Carvidol is started<br />and carefully monitored by a hospital specialist.<br />If you have stopped taking Carvidol for more than two weeks, you will need to return to the<br />starting dose and increase the dose gradually again.<br />Sometimes, your heart failure may worsen while taking Carvidol, particularly at the start of your<br />treatment. This may result in increased symptoms (e.g. tiredness, shortness of breath) and signs<br />of fluid retention (e.g. weight gain and swelling of the legs).<br />If your symptoms or condition worsen whilst taking Carvidol you should tell your doctor, as he<br />or she may need to change the dose of your other medications or of Carvidol.<br />While taking Carvidol, make sure that you continue with your other treatments for heart failure<br />as advised by your doctor.<br />Patients with liver problems<br />Depending on your condition, your doctor may reduce your dose compared to those<br />recommended above.<br />Children and adolescents (under 18 years old)<br />Carvidol are not recommended in this age group.</p><p>If you take more Carvidol than you should<br />If you accidentally take too many tablets, contact your doctor immediately or go to the nearest<br />hospital casualty department. You may feel dizzy, sick, faint, breathless/wheezy, very drowsy, or<br />experience convulsions.<br />If you forget to take Carvidol<br />If you forget to take a dose, do not worry. Take another as soon as you remember, provided it is<br />not nearly time for your next dose. Take your next tablet at the normal time, but do not take a<br />double dose to make up for a forgotten tablet.<br />If you stop taking Carvidol<br />Do not suddenly stop taking Carvidol before you have spoken to your doctor about it. You may<br />have side effects if you suddenly stop the tablets. Your doctor will tell you how to reduce the<br />dosage gradually and then stop this medicine. If you are also taking a medicine called clonidine,<br />never stop either treatment unless told to by your doctor.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The frequency of possible side effects is shown in the table below:<br />Very common: occur in more than 1 in 10 users.<br />Common: occur in less than 1 in 10, but more than 1 in 100 users.<br />Uncommon: occur in less than 1 in 100 users but more than 1 in 1.000 users.<br />Rare: occur in less than 1 in 1.000, but more than 1 in 10.000 users.<br />Very rare: occur in less than 1 in 10.000 users.<br />The majority of side effects are dose-related and disappear when the dose is reduced or the<br />treatment discontinued. Some side effects can occur at the beginning of treatment and resolve<br />spontaneously as the treatment continues.<br />Very common:<br />&bull; Dizziness,<br />&bull; Headache,<br />&bull; Tiredness,<br />&bull; Low blood pressure,<br />&bull; Heart failure.<br />Common:<br />&bull; Bronchitis, pneumonia, upper respiratory tract infection,<br />&bull; Infections of the urinary tract,<br />&bull; Low numbers of red blood cells,<br />&bull; Increase in weight,<br />&bull; Elevated cholesterol levels,<br />&bull; Loss of control of blood sugar in people with diabetes,<br />&bull; Depression, depressed mood,<br />&bull; Visual disturbance,</p><p>&bull; Reduced lacrimation, eye irritation,<br />&bull; Slow heart rate,<br />&bull; Oedema (swelling of the body or parts of the body), fluid overload, increased volume of<br />blood in the body,<br />&bull; Dizziness when standing up quickly,<br />&bull; Problems with blood circulation (signs include cold hands and feet), hardening of the arteries<br />(atherosclerosis) worsening of symptoms in patients with Raynaud&#39;s disease (fingers or toes<br />turn first bluish, then whitish, and then reddish together with pain) or claudication (pain in<br />the legs which worsens when walking),<br />&bull; Asthma and breathing problems,<br />&bull; Fluid accumulation in the lungs,<br />&bull; Diarrhoea,<br />&bull; Malaise, vomiting, stomach pains and indigestion,<br />&bull; Pains (e.g. in the arms and legs),<br />&bull; Acute renal insufficiency and disturbances in renal function in patients with hardening of the<br />arteries and/or impaired renal function,<br />&bull; Difficulty in passing urine.<br />&bull; Hyperkalemia.<br />Uncommon:<br />&bull; Sleep disturbance,<br />&bull; Confusion,<br />&bull; Fainting,<br />&bull; Abnormal sensation,<br />&bull; Disturbances in the heart&#39;s conduction system, angina pectoris (including chest pain),<br />&bull; Certain skin reactions (e.g. allergic dermatitis, hives, itching and skin inflammation,<br />increased sweating, psoriatic or lichen planus like skin lesions),<br />&bull; Hair loss,<br />&bull; Impotence.<br />Rare:<br />&bull; Lowered blood platelet count (thrombocytopenia),<br />&bull; Mouth dryness (dryness of the mouth),<br />&bull; Stuffy nose.<br />Very rare:<br />&bull; Low numbers of white blood cells,<br />&bull; Allergic reactions,<br />&bull; Changes in the liver function test,<br />&bull; Involuntary leakage of urine in women (urinary incontinence),<br />&bull; Skin and subcutaneous tissue disorders: such as severe cutaneous adverse reactions (Toxic<br />epidermal necrolysis and Stevens-Johnson syndrome), so If you experience severe cutaneous&nbsp;adverse reactions possibly attributable to carvedilol, stop taking this medicine and tell your<br />doctor immediately.<br />If you get any side effects, talk to your doctor or pharmacist. This<br />includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry<br />date refers to the last day of that month.<br />Store below 25&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is carvedilol. Each tablet contains 6.25 mg, 12.5 mg or 25 mg<br />carvedilol.<br />&bull; The other ingredients are: lactose, Maize Starch, Microcrystalline Cellulose (Avicel pH 102),<br />Hydroxypropyl Cellulose, Colloidal Silicon Dioxide, Magnesium Stearate, Purified Talc and<br />Iron Oxide Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Carvidol 6.25mg Tablets: A white to off-white round biconvex uncoated tablet with a breakline
on one side and engraved with “187” on other side.
Carvidol 12.5mg Tablets: Cream coloured, round, biconvex uncoated tablet with a breakline on
one side and “188” on other side.
Carvidol 25mg Tablets: Light pink coloured, round, biconvex uncoated tablet with a breakline
on one side and “189” on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO<br />AlQassim pharmaceutical plant<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>كارفیدول ھو مستحضر دوائى یحتوى على مادة كارفیدیلول كمادة فعالة.<br />تنتمى مادة كارفیدیلول إلى مجموعة من الأدویة التى تعرف باسم مثبطات- بیتا والتى تعمل على توسیع وارتخاء الأوعیة<br />الدمویة. مما یزید من سھولة ضخ الدم من قبل القلب إلى جمیع أنحاء الجسم والعمل على خفض كل من ضغط الدم وإجھاد<br />القلب.<br />یستخدم كارفیدول:<br />&bull; ل علاج ارتفاع ضغط الدم،<br />&bull; ل علاج آلام الصدر التي تحدث عندما یتم تضییق الشرایین التي تزود القلب بالدم المحمل بالأكسجین مما یؤدي نقص كمیة<br />الأكسجین الواصل إلى عضلة القلب (الذبحة الصدریة)،<br />&bull; ل علاج ضعف عضلة القلب (قصور القلب)، بالاقتران مع بعض الأدویة الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول كارفیدول فى الحالات الآتیة:<br />&bull; إ ذا كنت تعانى من فرط التحسس (الحساسیة) تجاه مادة كارفیدیلول أو تجاه أى من المكونات الأخرى لھذا الدواء<br />(والمذكورة فى الفقرة 6 &quot;معلومات إضافیة&quot;).</p><p>&bull; إ ذا كان لدیك تاریخ من الأزیز بالصدر نتیجة الإصابة بربو أو أمراض أخرى بالرئة،<br />&bull; إ ذا تم إبلاغك بإصابتك بفشل حاد جداً بالقلب وكان لدیك احتباس للسوائل (تورم) والذي یعالج بحقنك فى الورید ببعض<br />الأدویة،<br />&bull; إ ذا كنت مصابا بمرض بالكبد،<br />&bull; إ ذا تم إبلاغك بأن لدیك بطء شدید فى ضربات القلب،<br />&bull; إ ذا كان لدیك انخفاض شدید فى ضغط الدم،<br />&bull; إ ذا تم إبلاغك بأن لدیك حالة من الذبحة الصدریة التى تعرف باسم برنزمیتال،<br />&bull; إ ذا كان لدیك ورم القواتم (وھو ورم بالغدة الكظریة والذى یسبب ارتفاع ضغط الدم) والذى لم یتم علاجھ،<br />&bull; إ ذا كنت تعاني من اضطرابات خطیرة في التوازن الحمضي القاعدي في الجسم (الحماض الأیضي)،<br />&bull; إ ذا كان لدیك قصور حاد فى الدورة الدمویة بالیدین والقدمین مما یسبب برودة وألم بھم،<br />ما لم یتم تركیب جھاز لتنظیم ) AV &bull; إ ذا كان لدیك خلل معین فى التوصیل بالقلب (والذى یسمى إحصار القلب بالحزمة<br />،(SA ضربات القلب) أو إحصار القلب بالحزمة<br />&bull; إ ذا كنت تخضع حالیا للعلاج عن طریق الحقن بواسطة فیرابامیل أو دیلتیازیم (والتى تستخدم في علاج ارتفاع ضغط الدم<br />أو مشاكل في القلب).<br />فى حالة انطباق أى من الحالات المذكورة أعلاه علیك، لا تقم بتناول أقراص كارفیدول.<br />تحذیرات واحتیاطات<br />من الضرورى علیك أن تخبر طبیبك المعالج قبل البدء فى تناول أقراص كارفیدول فى الحالات الآتیة:<br />&bull; إ ذا تم إبلاغك بأنك تعانى من أى مشاكل أخرى بالقلب،<br />&bull; إ ذا كنت تعانى حالیا أو مسبقا فى أى وقت مضى من أى مشاكل بالكبد أو الكلى أو الغدة الدرقیة،<br />&bull; إ ذا كنت مصابا بداء السكرى. حیث قد یخفى كارفیدول الأعراض المعتادة لنقص مستوى السكر لدیك بالدم،<br />&bull; إ ذا كنت تعانى من حالة مرضیة بالجلد تعرف باسم الصدفیة،<br />&bull; إ ذا كان لدیك قصور فى الدورة الدمویة مما یؤثر على الیدین والقدمین أو الساقین، أو لدیك ظاھرة رینود،<br />&bull; إ ذا كان لدیك حالیاً أو مسبقاً فى أى وقت مضى تفاعل تحسسى حاد أو إذا كنت تخضع للعلاج بواسطة أدویة لإزالة<br />الحساسیة لأى نوع من أنواع الحساسیة الحادة،<br />&bull; إ ذا كنت تستخدم العدسات اللاصقة حیث قد یزید كارفیدول من جفاف العینین عن المعدل الطبیعي.<br />تحذیرات</p><p>تأثیرات جانبیة شدیدة على الجلد:<br />ومتلازمة (TEN) &bull; قد تم الإبلاغ عن حالات نادرة جدا من التأثیرات الجانبیة الجلدیة الشدیدة مثل انحلال البشرة السمي<br />أثناء فترة العلاج بأقراص كارفیدول [انظر الفقرة 4 (الأعراض الجانبیة المحتملة)]. (SJS) ستیفنز جونسون<br />تناول أدویة أخرى مع كارفیدول<br />أخبر طبیبك المعالج أو الصیدلى بشأن أى أدویة أخرى تتناولھا حالیا أو قد تتناولھا أو تناولتھا مؤخر ا.ً<br />كیفیة تناول أقراص كارفیدول:<br />فضلا أخبر طبیبك المعالج أو الصیدلى بشأن أى أدویة أخرى تتناولھا حالیا أو تناولتھا مؤخرا،ً بما فیھا تلك الأدویة التى<br />حصلت علیھا بدون وصفة طبیة أو الأدویة العشبیة. ینبغى توخى الحذر بشكل خاص وإبلاغ طبیبك المعالج أو الصیدلى فى<br />حالة تناولك لأى من الأدویة التالیة:<br />&bull; أ دویة تستخدم لعلاج عدم انتظام ضربات القلب (مثل دیلتیازیم أو فیرابامیل أو أمیودارون)،<br />&bull; أ دویة النیترات لعلاج الذبحة الصدریة (مثل أیزوسوربید أحادي النیترات أو جلیسیریل ثلاثي النیترات)،<br />&bull; أ دویة لعلاج فشل القلب (مثل دیجوكسین)،<br />&bull; أ ى أدویة أخرى لعلاج ارتفاع ضغط الدم (مثل دوكسازوسین أو ریسیربین أو أملودیبین أو إندورامین)،<br />&bull; ا لأدویة المستخدمة لعلاج الاكتئاب أو علاج حالات أخرى صحیة عقلیة (مثل فلوكستین، أو مضادات الاكتئاب ثلاثیة<br />،(MAOls) الحلقات أو الباربیتورات أو الفینوثیازین أو ھالوبیریدول أو مثبطات أكسید أحادي الأمین<br />&bull; ا لأدویة المستخدمة لمنع رفض الجسم للأعضاء بعد عملیات زرع الأعضاء (مثل سیكلوسبورین)،<br />&bull; ا لأدویة المستخدمة لخفض نسبة السكر في الدم مثل الأدویة المضادة لمرض السكر عن طریق الفم أو الإنسولین،<br />&bull; ا لأدویة المستخدمة لخفض ضغط الدم أو لعلاج الصداع النصفي (مثل كلونیدین أو إرجوتامین)،<br />&bull; أ دویة معینة لتسكین الألم مثل الأدویة المضادة للالتھابات غیر الستیرویدیة (المسكنات) (مثل إیبوبروفین أو دیكلوفیناك)،<br />&bull; ا لأدویة المستخدمة كعلاج بالھرمونات البدیلة (مثل ھرمون الإستروجین)،<br />&bull; ا لكورتیزونات المستخدمة لقمع التفاعلات الالتھابیة أو الحساسیة (مثل بریدنیزولون)،<br />&bull; ا لأدویة المستخدمة لعلاج العدوى البكتیریة (مثل ریفامبیسین أو إریثرومیسین)،<br />&bull; ا لأدویة المستخدمة لعلاج قرحة المعدة، وحرقة المعدة وارتجاع الحمض (مثل سیمیتیدین)،<br />&bull; ا لأدویة المستخدمة لعلاج العدوى الفطریة (مثل كیتوكونازول)،<br />&bull; ا لأدویة المستخدمة في بعض الأحیان في السعال ونزلات البرد والاحتقان (مثل إیفیدرین أو سودوإیفیدرین).<br />إذا كنت في حاجة إلى استخدام مخدر لإجراء عملیة، أخبر طبیبك المعالج بالمستشفى بأنك تتناول كارفیدول.</p><p>تناول أقراص كارفیدول مع الطعام والشراب<br />ینبغى علیك تناول كارفیدول مع الماء.<br />إذا كنت تتناول أقراص كارفیدول لعلاج فشل القلب، یجب علیك تناول ھذا الدواء مع الماء فى وقت الطعام (انظر الفقرة 3<br />&quot;كیفیة تناول كارفیدول&quot;).<br />لا تقم بشرب الكحول أثناء تناول كارفیدول حیث قد یزید ذلك من سوء تأثیرات الكحول.<br />الحمل والرضاعة<br />إذا كنتِ حاملا أو ترضعین طفلك طبیعیا لا تقومى بتناول ھذا الدواء إلا بعد مناقشة ھذا الأمر مع طبیبك المعالج. استشیرى<br />طبیبك المعالج فورا إذا ما أصبحتِ حاملا أثناء تناولك لھذا الدواء. اسألى طبیبك المعالج أو الصیدلى للمشورة قبل تناول أى<br />أدویة.<br />القیادة واستخدام الآلات<br />قد تتعرض إلى حدوث دوخة أو تعب أثناء تناول كارفیدول. وھذا ھو أكثر احتمالاً أن یحدث فى بدایة تناول العلاج، أو عند<br />زیادة الجرعة. إذا حدث ھذا، یجب علیك عدم قیادة السیارة أو تشغیل الآلات. یجب تجنب شرب الكحول، لأنھ قد یجعل ھذه<br />الأعراض أسوأ. إذا كنت تشعر بالقلق أو ترید المزید من المعلومات، یجب علیك التحدث مع طبیبك المعالج.<br />معلومات ھامة حول بعض مكونات كارفیدول<br />أقراص كارفیدول تحتوى على لاكتوز. لذلك، إذا تم إبلاغك من قبل الطبیب المعالج بعدم تحملك لبعض أنواع السكریات،<br />تواصل مع طبیبك المعالج قبل البدء فى تناول ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب علیك دائما تناول ھذا الدواء تماما كما وصف لك طبیبك المعالج. وفى حالة عدم تأكدك، تحقق من خلال طبیبك المعالج أو<br />الصیدلى.<br />یجب علیك ابتلاع قرص كارفیدول مع شرب الماء.<br />لعلاج ارتفاع ضغط الدم<br />للبالغین: جرعة البدایة المعتادة تكون 12.5 ملجم مرة واحدة یومیا لأول یومین.<br />بعد ذلك، یتم زیادة الجرعة إلى 25 ملجم مرة واحدة یومیا .ً إذا لزم الأمر، قد یلجأ طبیبك المعالج إلى زیادة الجرعة تدریجیا على مدار أسبوعین أو أكثر. الحد الأقصى للجرعة الیومیة ھو 50 ملجم (الحد الأقصى للجرعة الوحیدة ھو 25 ملجم).<br />لكبار السن: عادة سوف یبدأ طبیبك المعالج بجرعة 12.5 ملجم مرة واحدة یومیا ویستمر علیھا طول فترة علاجك. إذا لزم<br />الأمر، قد یلجأ طبیبك المعالج إلى زیادة الجرعة تدریجیا على مدار أسبوعین أو أكثر.<br />لعلاج الذبحة الصدریة<br />للبالغین: جرعة البدایة المعتادة تكون 12.5 ملجم مرتین یومیا لأول یومین.</p><p>بعد ذلك، یتم زیادة الجرعة إلى 25 ملجم مرتین یومیا .ً إذا لزم الأمر، قد یلجأ طبیبك المعالج إلى زیادة الجرعة تدریجیا على<br />مدار أسبوعین أو أكثر إلى حد أقصاه 100 ملجم فى الیوم مقسمة على جرعتین.<br />لكبار السن: جرعة البدایة الموصى بھا ھى 12.5 ملجم مرتین یومیا لأول یومین.<br />بعد ذلك، قد یتم زیادة الجرعة إلى 25 ملجم مرتین یومیا،ً وھو الحد الأقصى المسموح بھ للجرعة الیومیة.<br />لعلاج فشل القلب<br />للبالغین وكبار السن: لعلاج الفشل القلبى المستقر، یجب تناول الأقراص مرتین یومیا،ً مرة صباحا ومرة مساءً، وینبغى تناول<br />العلاج مع الطعام للحد من خطورة الأعراض الجانبیة.<br />جرعة البدایة ھى 3.125 ملجم مرتین یومیا لمدة أسبوعین. ثم سیقوم طبیبك المعالج بزیادة الجرعة تدریجیا على مدار<br />أسبوعین أو أكثر حتى تصل إلى الجرعة الأنسب لحالتك.<br />إذا كان وزنك أقل من 85 كجم، فإن الحد الأقصى للجرعة من أقراص كارفیدول یكون 25 ملجم مرتین یومیا،ً وإذا كان وزنك<br />أكثر من 85 كجم، قد یزید طبیبك المعالج الجرعة إلى 50 ملجم مرتین یومی ا.ً<br />لعلاج الفشل القلبى، من الموصى بھ أن یبدأ علاجك بأقراص كارفیدول ویتم مراقبة العلاج بحرص من قبل أخصائى<br />بالمستشفى.<br />إذا توقفت عن تناول أقراص كارفیدول لمدة تزید عن أسبوعین، سوف تحتاج إلى العودة إلى جرعة البدایة وزیادة الجرعة<br />تدریجیا مرة أخرى.<br />أحیاناً، قد تسوء حالة فشل القلب لدیك أثناء تناول أقراص كارفیدول، خصوصاً فى بدایة تناول العلاج. مما قد یؤدى إلى زیادة<br />الأعراض (مثل الإرھاق وقصور فى التنفس) وعلامات احتباس السوائل (مثل زیادة الوزن وتورم الساقین).<br />إذا زادت لدیك الأعراض أو سائت حالتك أثناء تناول أقراص كارفیدول، أخبر طبیبك المعالج فقد یلجأ إلى تغییر الجرعة<br />الخاصة بك من كارفیدول أو من الأدویة الأخرى.<br />أثناء تناول كارفیدول تأكد من استمرار تناولك للأدویة الأخرى المصاحبة لھ لعلاج الفشل القلبى طبقا لوصف الطبیب.<br />المرضى ذوى مشاكل بالكبد<br />اعتماداً على حالتك قد یلجأ طبیبك المعالج إلى وصف جرعات أقل من تلك الموصوفة أعلاه.<br />الأطفال والمراھقین (الأقل فى العمر من 18 سنة)<br />لا ینصح باستخدام كارفیدول للمرضى فى ھذه الفئة العمریة.<br />فى حالة تناول كارفیدول أكثر مما ینبغى<br />فى حالة تناولك العدید من أقراص كارفیدول عن طریق الخطأ، تواصل مع طبیبك المعالج فوراً أو توجھ إلى قسم الطوارئ<br />بأقرب مستشفى. قد تشعر بدوخة أو إعیاء أو إغماء أو قصور فى التنفس/أزیز بالصدر أو دوار شدید أو تتعرض لتشنجات.<br />فى حالة نسیان تناول أقراص كارفیدول</p><p>إذا نسیت تناول الجرعة الخاصة بك من أقراص كارفیدول، لا تقلق. قم بتناول الجرعة حالما تتذكر، إلا إذا كان قد اقترب موعد<br />الجرعة التالیة. فى ھذه الحالة قم بتناول الجرعة التالیة فى موعدھا ولا تقم بتناول جرعة مضاعفة لتعویض الجرعة المنسیة.<br />فى حالة التوقف عن تناول كارفیدول<br />لا تتوقف بشكل مفاجئ عن تناول أقراص كارفیدول قبل إبلاغ طبیبك المعالج بھذا الشأن. فقد تتعرض إلى أعراض جانبیة عند<br />التوقف المفاجئ عن تناول ھذا الدواء. سوف یخبرك طبیبك المعالج كیف تقلل الجرعة تدریجیا ثم تتوقف بعد ذلك عن تناول ھذا<br />الدواء. إذا كنت تتناول أیضا دواء یسمى كلونیدین، لا تتوقف أبدا عن تناول العلاج إلا إذا أخبرك طبیبك المعالج بذلك.<br />إذا كانت لدیك أى أسئلة إضافیة حول استخدام ھذا الدواء، اسأل طبیبك المعالج أو الصیدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة، قد یسبب كارفیدول أعراضا جانبیة وإن لم تكن تحدث لكل من یتناول ھذا الدواء.<br />المصطلحات التالى ذكرھا تستخدم لوصف معدل تكرار حدوث الأعراض الجانبیة التى تم رصدھا لھذا الدواء:<br />أعراض جانبیة شائعة جدا (والتى تصیب أكثر من 1 لكل 10 مرضى مستخدمین لھذا الدواء).<br />أعراض جانبیة شائعة (والتى تصیب أقل من 1 لكل 10 ولكن أكثر من 1 لكل 100 مستخدم لھذا الدواء).<br />أعراض جانبیة غیر شائعة (والتى تصیب أقل من 1 لكل 100 وأكثر من 1 لكل 1000 مستخدم لھذا الدواء).<br />أعراض جانبیة نادرة (والتى تصیب أقل من 1 لكل 1000 وأكثر من 1 لكل 10,000 مستخدم لھذا الدواء).<br />أعراض جانبیة نادرة جداً (والتى تصیب أقل من 1 لكل 000،10 مستخدم لھذا الدواء).<br />معظم الأعراض الجانبیة تعتمد على الجرعة وتختفى عند خفض الجرعة أو التوقف عن تناول العلاج. بعض الأعراض<br />الجانبیة قد تحدث فى بدایة العلاج وتزول بصورة تلقائیة عند الاستمرار فى تناول العلاج.<br />أعراض جانبیة شائعة جد ا:ً<br />&bull; دوخة،<br />&bull; صداع،<br />&bull; إ رھاق،<br />&bull; ا نخفاض ضغط الدم،<br />&bull; فشل القلب.<br />أعراض جانبیة شائعة:<br />&bull; ا لتھاب الشعب الھوائیة والالتھاب الرئوي وعدوى الجھاز التنفسي العلوي،<br />&bull; عدوى المسالك البولیة،<br />&bull; ا نخفاض عدد خلایا الدم الحمراء،</p><p>&bull; زیادة في الوزن،<br />&bull; ا رتفاع مستویات الكولستیرول،<br />&bull; فقدان السیطرة على نسبة السكر في الدم عند مرضى السكري،<br />&bull; ا لاكتئاب والمزاج المكتئب،<br />&bull; ا لاضطرابات البصریة،<br />&bull; ا نخفاض إدماع العینین وتھیج العین،<br />&bull; ب طء معدل ضربات القلب،<br />&bull; وذمة (تورم في الجسم أو أجزاء من الجسم) واحتباس السوائل، وزیادة حجم الدم في الجسم،<br />&bull; ا لدوخة عند الوقوف بسرعة،<br />&bull; مشاكل فى الدورة الدمویة (تشمل علامات برودة الیدین والقدمین)، تصلب الشرایین وتفاقم الأعراض في المرضى الذین<br />یعانون من مرض رینود (تحول أصابع الیدین أو القدمین إلى اللون الأزرق ثم الأبیض ثم الأحمر مع وجود ألم) أو العرج<br />(وھو ألم في الساقین والذي یسوء عند المشي)،<br />&bull; ا لربو ومشاكل في التنفس،<br />&bull; ت راكم السوائل في الرئتین،<br />&bull; ا لإسھال،<br />&bull; ا لشعور بالضیق، والتقیؤ، وآلام في المعدة، وعسر الھضم،<br />&bull; آ لام (على سبیل المثال في الذراعین والساقین)،<br />&bull; ا لقصور الكلوي الحاد واضطرابات في وظائف الكلى في المرضى الذین یعانون من تصلب الشرایین و / أو اختلال وظائف<br />الكلى،<br />&bull; صعوبة في التبول.<br />&bull; ا رتفاع نسبة البوتاسیوم في الدم.<br />أعراض جانبیة غیر شائعة:<br />&bull; ا ضطراب النوم،<br />&bull; ا رتباك،<br />&bull; إ غماء،</p><p>&bull; إ حساس غیر طبیعي،<br />&bull; ا لاضطرابات في نظام التوصیل للقلب أو الذبحة الصدریة (وتشمل ألم في الصدر)،<br />&bull; ت فاعلات معینة بالجلد (مثل الالتھابات التحسسیة بالجلد والشرى والحكة والتھاب الجلد، وزیادة التعرق، والصدفیة أو الحزاز<br />المسطح مثل تقرحات الجلد)،<br />&bull; فقدان الشعر،<br />&bull; ا لعجز الجنسي.<br />أعراض جانبیة نادرة:<br />&bull; ا نخفاض عدد صفائح الدم (الصفیحات)،<br />&bull; جفاف الفم،<br />&bull; ا نسداد الأنف.<br />أعراض جانبیة نادرة جد ا:ً<br />&bull; ا نخفاض عدد خلایا الدم البیضاء،<br />&bull; حساسیة ،<br />&bull; ت غییرات في اختبار وظائف الكبد،<br />&bull; ت سرب البول اللاإرادي لدى النساء (السلس البولى)،<br />&bull; ا ضطرابات بالجلد والأنسجة تحت الجلد: مثل التأثیرات الجانبیة الشدیدة على الجلد (مثل انحلال البشرة السمى ومتلازمة<br />ستیفنز جونسون)، لذلك إذا تعرضت لتأثیرات جانبیة جلدیة شدیدة قد تكون بسبب كارفیدول، توقف عن تناول ھذا الدواء،<br />وأخبر طبیبك المعالج فور ا.ً<br />إذا تعرضت لحدوث أى أعراض جانبیة، تواصل مع طبیبك المعالج أو الصیدلى. ویشمل ذلك أى أعراض جانبیة لم یتم ذكرھا<br />فى ھذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحفظ ھذا الدواء بعیدا عن نظر ومتناول الأطفال.<br />علما بأن تاریخ .&ldquo;EXP&rdquo; لا تقم بتناول ھذه الأقراص بعد انتھاء تاریخ الصلاحیة المدون على العبوة والشریط بعد كلمة<br />الصلاحیة یشیر إلى آخر یوم فى الشھر المذكور.<br />یحفظ فى درجة حرارة أقل من 25 درجة مئویة.<br />یجب عدم التخلص من الأدویة عبر میاه الصرف الصحى أو النفایات المنزلیة. اسأل الصیدلى عن كیفیة التخلص من الأدویة<br />التى لم تعد بحاجة إلیھا. فسوف تساعد ھذه التدابیر فى حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتویات أقراص كارفیدول:<br />&bull; ا لمادة الفعالة ھى كارفیدیلول. یحتوى كل قرص على 6.25 ملجم أو 12.5 ملجم أو 25 ملجم من المادة الفعالة كارفیدیلول.<br />ھیدروكسي بروبیل سلیولوز، ثاني ،(PH &bull; مكونات أخرى وھى: لاكتوز، نشا الذرة، سلیولوز دقیق التبلور (أفیسیل 102<br />أكسید سیلیكون غروى، ستیارات مغنسیوم، تلك منقى وأكسید الحدید الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كارفیدول 6.25 ملجم أقراص: ھى أقراص مستدیرة ثنائیة التحدب غیر مغلفة لونھا من أبیض إلى أبیض فاتح بھا خط فاصل<br />على جانب واحد ومحفور رقم &quot; 187 &quot; على الجانب الآخر.<br />كارفیدول 12.5 ملجم أقراص: ھى أقراص مستدیرة ثنائیة التحدب غیر مغلفة لونھا أصفر شاحب بھا خط فاصل على جانب<br />واحد ومحفور رقم &quot; 188 &quot; على الجانب الآخر.<br />كارفیدول 25 ملجم أقراص: ھى أقراص مستدیرة ثنائیة التحدب غیر مغلفة لونھا وردى فاتح بھا خط فاصل على جانب واحد<br />ومحفور رقم &quot; 189 &quot; على الجانب الآخر.<br />حجم العبوة: كل عبوة تحتوى على 30 قرص ا.ً</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الدوائیة<br />مصنع الأدویة بالقصیم<br />المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابریل 2019 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carvidol 12.5 mg. 
Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Carvidol 12.5 mg: Each tablet contains 12.5 mg of carvedilol.
Excipients: 
Carvidol 12.5 mg: Each tablet contains 72 mg of lactose.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets 
Carvidol 12.5mg  Tablets: Cream coloured, round, biconvex uncoated tablet with a breakline on one side and “188” on other side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Essential hypertension</p><p>Chronic stable angina pectoris</p><p>Adjunctive treatment of moderate to severe stable chronic heart failure</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral use.</p><p><strong>Essential Hypertension</strong></p><p>Carvedilol may be used for the treatment of hypertension alone or in combination with other antihypertensives, especially thiazide diuretics. Once daily dosing is recommended, however the recommended maximum single dose is 25 mg and the recommended maximum daily dose is 50 mg.</p><p><em>Adults:</em></p><p>The recommended initial dose is 12.5 mg once a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg/day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely.</p><p><em>Elderly:</em></p><p>The recommended initial dose in hypertension is 12.5 mg once a day which may also be sufficient for continued treatment.</p><p>However, if the therapeutic response is inadequate at this dose, the dose may be further increased gradually at intervals of two weeks or more rarely.</p><p><strong>Chronic stable angina pectoris:</strong></p><p>A twice-daily regimen is recommended.</p><p><em>Adults</em></p><p>The recommended initial dosage is 12.5 mg twice a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg twice a day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely to the recommended maximum dose of 100 mg a day divided into two doses (twice daily).</p><p><em>Elderly</em></p><p>The recommended initial dose is 12.5 mg twice daily for two days. Thereafter, the treatment is continued at the dose 25 mg twice daily, which is the recommended maximum daily dose.</p><p><strong>Heart Failure:</strong></p><p>Carvedilol is given in moderate to severe heart failure in addition to conventional basic therapy with diuretics, ACE inhibitors, digitalis, and/or vasodilators. The patient should be clinically stable (no change in NYHA-class, no hospitalisation due to heart failure) and the basic therapy must be stabilized for at least 4 weeks prior to treatment. Additionally the patient should have a reduced left ventricular ejection fraction and heart rate should be &gt; 50 bpm and systolic blood pressure &gt; 85 mm Hg (see section 4.3).</p><p>The initial dose is 3.125 mg twice a day for two weeks. If this dose is tolerated, the dose may be increased slowly with intervals of not less than two weeks up to 6.25 mg twice a day, then up to 12.5 mg twice a day and finally up to 25 mg twice a day. The dosage should be increased to the highest tolerable level.</p><p>The recommended maximum dosage is 25 mg twice a day for patients with a body weight of less than 85 kg, and 50 mg twice a day for patients with a body weight above 85 kg, provided that the heart failure is not severe.&nbsp;<u>A dose increase to 50 mg twice daily should be performed carefully under close medical supervision of the patient.</u></p><p>Transient worsening of symptoms of heart failure may occur at the beginning of treatment or due to a dose increase, especially in patients with severe heart failure and/or under high dose diuretic treatment. This does usually not call for discontinuation of treatment, but dose should not be increased. The patient should be monitored by a physician/cardiologist for two hours after starting treatment or increasing the dose. Before each dose increase, an examination should be performed for potential symptoms of worsening heart failure or for symptoms of excessive vasodilatation (e.g. renal function, body weight, blood pressure, heart rate and rhythm). Worsening of heart failure or fluid retention is treated by increasing the dose of diuretic, and the dose of carvedilol should not be increased until the patient is stabilized. If bradycardia appears or in case of lengthening of AV conduction, the level of digoxin should first be monitored. Occasionally it may be necessary to reduce the carvedilol dose or temporarily discontinue treatment altogether. Even in these cases, carvedilol dose titration can often be successfully continued.</p><p>Renal function, thrombocytes and glucose (in case of NIDDM and/or IDDM) should be monitored regularly during dose titration. However, after dose titration the frequency of monitoring can be reduced.</p><p>If carvedilol has been withdrawn for more than two weeks, the therapy should be reinitiated with 3.125 mg twice a day and increased gradually according to the above recommendations.</p><p><em>Renal insufficiency</em></p><p>Dosage must be determined for each patient individually, but according to pharmacokinetic parameters there is no evidence that dose adjustment of carvedilol in patients with renal impairment is necessary.</p><p><em>Moderate hepatic dysfunction</em></p><p>Dose adjustment may be required.</p><p><em>Children and adolescents (&lt; 18 years)</em></p><p>Carvidol is not recommended for the use in children below 18 years of age due to insufficient data on the efficacy and safety of carvedilol.</p><p><em>Elderly</em></p><p>Elderly patients may be more susceptible to the effects of carvedilol and should be monitored more carefully.</p><p>As with other beta-blockers and especially in patients with coronary disease, the withdrawal of carvedilol should be done gradually (see section 4.4).</p><p><em>Methods of administration</em></p><p>The tablets should be taken with the adequate supply of fluid. It is recommended that heart failure patients take their carvedilol medication with food to allow the absorption to be slower and the risk of orthostatic hypotension to be reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the carvedilol or to any of the excipients of Carvedilol listed in section 6.1.
• Heart failure belonging to NYHA Class IV of the heart failure classification with marked fluid retention or overload requiring intravenous inotropic treatment.
• Chronic obstructive pulmonary disease with bronchial obstruction (see section 4.4).
• Clinically significant hepatic dysfunction.
• Bronchial asthma.
• AV block, degree II or III (unless a permanent pacemaker is in place).
• Severe bradycardia (<50 bpm).
• Sick sinus syndrome (incl. sino-atrial block).
• Cardiogenic shock.
• Severe hypotension (systolic blood pressure below 85 mmHg).
• Prinzmetal's angina.
• Untreated phaeochromocytoma.
• Metabolic acidosis.
• Severe peripheral arterial circulatory disturbances.
Concomitant intravenous treatment with verapamil or diltiazem (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Severe cutaneous adverse reactions (SCARs)</p><p>Very rare cases of severe cutaneous adverse reactions such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with carvedilol. Carvedilol should be permanently discontinued in patients who experience severe cutaneous adverse reactions possibly attributable to carvedilol.</p><p><u>Warnings to be considered particularly in heart failure patients</u></p><p>In chronic heart failure patients carvedilol should be administered principally in addition to diuretics, ACE inhibitors, digitalis and/or vasodilators. Initiation of therapy should be under the supervision of a hospital physician. Therapy should only be initiated, if the patient is stabilized on conventional basic therapy for at least 4 weeks. Patients with severe heart failure, salt and volume depletion, elderly or patients with low basic blood pressure should be monitored for approximately 2 hours after the first dose or after dose increase as hypotension may occur. Hypotension due to excessive vasodilatation is initially treated by reducing the dose of the diuretic. If symptoms still persist, the dose of any ACE inhibitor may be reduced. At the start of therapy or during up-titration of Carvedilol worsening of heart failure or fluid retention may occur. In these cases, the dose of diuretic should be increased. However, sometimes it will be necessary to reduce or withdraw Carvedilol medication. The carvedilol dose should not be increased before symptoms due to the worsening of heart failure or hypotension due to vasodilatation are under control.</p><p>Reversible deterioration of renal function has been observed during carvedilol therapy in heart failure patients with low blood pressure (systolic &lt; 100 mm Hg), ischaemic heart disease and generalized atherosclerosis, and/or underlying renal insufficiency. In heart failure patients with these risk factors, renal function should be monitored during dose titration of carvedilol. If significant worsening of renal function occurs, the carvedilol dose must be reduced or therapy must be discontinued.</p><p>In patients with chronic heart failure treated with digitalis, carvedilol should be given with caution, as digitalis and carvedilol both lengthen the AV conduction time (see section 4.5).</p><p><u>Other warnings as regards carvedilol and beta-blockers in general</u></p><p>Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal&#39;s variant angina. There is no clinical experience with carvedilol in these patients, although the alpha-blocking activity of carvedilol may prevent such symptoms. However, caution should be taken in the administration of carvedilol to patients suspected of having Prinzmetal&#39;s variant angina.</p><p>Patients with a chronic obstructive pulmonary disease with a tendency towards bronchospasms who are not treated with oral or inhalation medicine should only be given carvedilol if the expected improvement outweighs the possible risk. Patients should be monitored closely in the initial phase, and titration of carvedilol and carvedilol dose should be reduced in case of bronchospasms.</p><p>Carvedilol may mask symptoms and signs of acute hypoglycaemia. Impaired blood glucose control may occasionally occur in patients with diabetes mellitus and heart failure in connection with the use of carvedilol. Therefore, close monitoring of diabetic patients receiving carvedilol is required by means of regular blood glucose measurements, especially during dose titration, and adjustment of antidiabetic medication as necessary (see section 4.5). Blood glucose levels should also be closely monitored after a longer period of fasting.</p><p>Carvedilol may mask features (symptoms and signs) of thyrotoxicosis.</p><p>Carvedilol may cause bradycardia. If there is a decrease in pulse rate to less than 55 beats per minute, and symptoms associated with bradycardia occur, the carvedilol dose should be reduced.</p><p>When carvedilol is used concomitantly with calcium channel blocking agents such as verapamil and diltiazem or with other antiarrhythmics, specifically amiodarone, the patient&#39;s blood pressure and ECG have to be monitored. Intravenous co-administration should be avoided (see section 4.5).</p><p>Cimetidine should be administered only with caution concomitantly as effects of carvedilol may be increased (see section 4.5).</p><p>Persons wearing contact lenses should be advised of a possible reduction of the secretion of lacrimal fluid.</p><p>Care should be taken in administrating carvedilol to patients with a history of serious hypersensitivity reactions and in those undergoing desensitisation therapy as beta-blockers may increase both the sensitivity towards allergens and the seriousness of anaphylactic reactions. Cautions should be exercised when prescribing beta-blockers to patients with psoriasis since skin reactions may be aggravated.</p><p>Carvedilol should be used with caution in patients with peripheral vascular diseases, as beta-blockers may aggravate symptoms of the disease. The same also applies to those with Raynaud&#39;s syndrome, as there may be exacerbation or aggravation of symptoms.</p><p>Patients who are known as poor metabolizers of debrisoquine, should be closely monitored during initiation of therapy (see section 5.2).</p><p>Since there is limited clinical experience, carvedilol should not be administered in patients with labile or secondary hypertension, orthostasis, acute inflammatory heart disease, haemodynamic relevant obstruction of heart valves or outflow tract, end-stage peripheral arterial disease, concomitant treatment with &alpha;1-receptor antagonist or &alpha;2-receptor agonist.</p><p>In patients with phaeochromocytoma, an initial treatment with alpha-blockers should be started before using any beta-blocker. Although carvedilol exercises alpha and beta blockade there is not sufficient experience in this disease, therefore caution should be advised in these patients.</p><p>Because of its negative dromotropic action, carvedilol should be given with caution to patients with first degree heart block.</p><p>Beta-blockers reduce the risk of arrhythmias at anasthesia, however the risk of hypotension may be increased as well. Caution should therefore be observed with the use of certain anaesthetic medicines. Newer studies suggest however, a benefit of beta-blockers in preventing perioperative cardiac morbidity and reduction of the incidence of cardiovascular complications.</p><p>As with other beta-blockers, carvedilol should not be discontinued abruptly. This applies in particular to patients with ischaemic heart disease. Carvedilol therapy must be discontinued gradually within two weeks, e.g. by reducing the daily dose to half every three days. If necessary, at the same time replacement therapy should be initiated to prevent exacerbation of angina pectoris.</p><p>Carvedilol contains lactose monohydrate and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Antiarrhythmics.</em></strong></p><p>Isolated cases of conduction disturbance (rarely compromised haemodynamics) have been reported, if oral carvedilol and oral diltiazem verapamil and/or amiodarone are given concomitantly. As with other beta-blockers, ECG and blood pressure should be monitored closely when concomitantly administering calcium-channel-blockers of the verapamil and diltiazem type due to the risk of AV conduction disorder or risk of cardiac failure (synergetic effect). Close monitoring should be done in case of co-administration of carvedilol, and amiodarone therapy (oral) or class I antiarrhythmics. Bradycardia, cardiac arrest, and ventricular fibrillation have been reported shortly after initiation of beta-blocker treatment in patients receiving amiodarone. There is a risk of cardiac failure in case of class Ia or Ic antiarrhythmics concomitant intravenous therapy.</p><p>Concomitant treatment with reserpine, guanethidine, methyldopa, guanfacine and monoamine oxidase inhibitors (exception MAO-B inhibitors) can lead to additional decrease in heart rate. And hypotension Monitoring of vital signs is recommended.</p><p><strong><em>Dihydropyridines.</em></strong></p><p>The administration of dihydropyridines and carvedilol should be done under close supervision as heart failure and severe hypotension have been reported.</p><p><strong><em>Nitrates.</em></strong></p><p>Increased hypotensive effects.</p><p><strong><em>Cardiac glycosides.</em></strong></p><p>An increase of steady state digoxin levels by approximately 16% and of digitoxin by approximately 13% has been seen in hypertensive patients in connection with the concomitant use of carvedilol and digoxin. Monitoring of plasma digoxin concentrations is recommended when initiating, discontinuing or adjusting treatment with carvedilol.</p><p><strong><em>Other antihypertensive medicines.</em></strong></p><p>Carvedilol may potentiate the effects of other concomitantly administered antihypertensives (e.g. &alpha;1-receptor antagonists) and medicines with antihypertensive adverse reactions such as barbiturates, phenothiazines, tricyclic antidepressants, vasodilating agents and alcohol.</p><p><strong><em>Cyclosporin.</em></strong></p><p>Modest increases in mean trough cyclosporine concentrations were observed following the initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection. In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations with the therapeutic range, while in the remainder no adjustment was needed. On average, the dose of cyclosporine was reduced about 20% in these patients. Due to wide interindividual variability in the dose adjustments required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.</p><p><strong><em>Antidiabetics including insulin.</em></strong></p><p>The blood sugar-lowering effect of insulin and oral diabetic medicines may be intensified. Symptoms of hypoglycaemia may be masked. In diabetic patients regular monitoring of blood glucose levels is necessary.</p><p><strong><em>Clonidine.</em></strong></p><p>In case of withdrawal of both carvedilol and clonidine, carvedilol should be withdrawn several days before the stepwise withdrawal of clonidine.</p><p><strong><em>Inhalational anaesthetics.</em></strong></p><p>Caution is advised in case of anaesthesia due to synergistic, negative inotrope and hypotensive effect of carvedilol and certain anaesthetics.</p><p><strong><em>NSAIDs, estrogens and corticosteroids.</em></strong></p><p>The antihypertensive effect of carvedilol is decreased due to water and sodium retention.</p><p><strong><em>Medicines inducing or inhibiting cytochrome P450 enzymes.</em></strong></p><p>Patients receiving medicines that induce (e.g. rifampicin and barbiturates) or inhibit (e.g. cimetidine, ketoconazole, fluoxetine, haloperidol, verapamil, erythromycine) cytochrome P450 enzymes have to be monitored closely during concomitant treatment with carvedilol as serum carvedilol concentrations may be reduced by the first agents and increased by the enzyme inhibitors.</p><p>Rifampicin reduced plasma concentrations of carvedilol by about 70%. Cimetidine increased AUC by about 30% but caused no change in Cmax. Care may be required in those patients receiving inducers of mixed function oxidases e.g. rifampicin, as serum levels of carvedilol may be reduced, or inhibitors of mixed function oxidases e.g. cimetidine, as serum levels may be increased. However, based on the relatively small effect of cimetidine on carvedilol drug levels, the likelihood of any clinically important interaction is minimal.</p><p><strong><em>Sympathomimetics with alpha-mimetic and beta-mimetic effects.</em></strong></p><p>Risk of hypertension and excessive bradycardia.</p><p><strong><em>Ergotamine.</em></strong></p><p>Vasoconstriction increased.</p><p><strong><em>Neuromuscular blocking agents.</em></strong></p><p>Increased neuromuscular block.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy category: C</p><p>There are no adequate data from the use of carvedilol in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Beta-blockers reduce placental perfusion which may result in intrauterine fetal death and immature and premature deliveries. In addition, adverse reactions (especially hypoglycaemia, hypotension, bradycardia, respiratory depression and hypothermia) may occur in the fetus and neonate. There is an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Carvedilol should not be used during pregnancy unless clearly necessary (that is if the potential benefit for the mother outweighs the potential risk for the fetus/neonate). The treatment should be stopped 2-3 days before expected birth. If this is not possible the new-born has to be monitored for the first 2-3 days of life.</p><p><u>Lactation</u></p><p>Carvedilol is lipophilic and according to results from studies with lactating animals, carvedilol and its metabolites are excreted in breast milk and, therefore, mothers receiving carvedilol should not breast-feed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product has minor influence on the ability to drive and use machines. Some individuals may have reduced alertness especially on initiation and adjustment of medication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>(a) Summary of the safety profile</em></p><p>The frequency of adverse reactions is not dose-dependent, with the exception of dizziness, abnormal vision and bradycardia.</p><p><em>(b) Tabulated list of adverse reactions</em></p><p>The risk of most adverse reactions associated with carvedilol is similar across all indications.</p><p>Exceptions are described in subsection (c).</p><p>Frequency categories are as follows:</p><p>Very common &ge; 1/10</p><p>Common &ge; 1/100 and &lt; 1/10</p><p>Uncommon &ge; 1/1,000 and &lt; 1/100</p><p>Rare &ge; 1/10,000 and &lt; 1/1,000</p><p>Very rare &lt; 1/10,000</p><p><em>Infections and infestations</em></p><p>Common: Bronchitis, pneumonia, upper respiratory tract infection, urinary tract infection</p><p><em>Blood and lymphatic system disorders</em></p><p>Common: Anaemia</p><p>Rare: Thrombocytopaenia</p><p>Very rare: Leukopenia</p><p><em>Immune system disorders</em></p><p>Very rare: Hypersensitivity (allergic reaction)</p><p><em>Metabolism and nutrition disorders</em></p><p>Common: Weight increase, hypercholesterolaemia, impaired blood glucose control (hyperglycaemia, hypoglycaemia) in patients with pre-existing diabetes</p><p><em>Psychiatric disorders</em></p><p>Common: Depression, depressed mood</p><p>Uncommon: Sleep disorders, confusion</p><p><em>Nervous system disorders</em></p><p>Very common: Dizziness, headache</p><p>Uncommon: Presyncope, syncope, paraesthesia</p><p><em>Eye disorders</em></p><p>Common: Visual impairment, lacrimation decreased (dry eye), eye irritation</p><p><em>Cardiac disorders</em></p><p>Very common: Cardiac failure</p><p>Common: Bradycardia, oedema, hypervolaemia, fluid overload</p><p>Uncommon: Atrioventricular block, angina pectoris</p><p><em>Vascular disorders</em></p><p>Very common: Hypotension</p><p>Common: Orthostatic hypotension, disturbances of peripheral circulation (cold extremities, peripheral vascular disease, exacerbation of intermittent claudication and Reynaud&#39;s phenomenon)</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Common: Dyspnoea, pulmonary oedema, asthma in predisposed patients</p><p>Rare: Nasal congestion</p><p><em>Gastrointestinal disorders</em></p><p>Common: Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain</p><p>Rare: dry mouth</p><p><em>Hepatobiliary disorders</em></p><p>Very rare: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gammaglutamyltransferase (GGT) increased</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Very rare: Severe cutaneous adverse reactions (Toxic epidermal necrolysis, Stevens-Johnson syndrome (see section 4.4 Warnings and Precautions)</p><p>Uncommon: Skin reactions (e.g. allergic exanthema, dermatitis, urticaria, pruritus, psoriatic and lichen planus like skin lesions and increased sweating), alopecia</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Common: Pain in extremities</p><p><em>Renal and urinary disorders</em></p><p>Common: Renal failure and renal function abnormalities in patients with diffuse vascular disease and/or underlying renal insufficiency, micturition disorders</p><p>Very rare: Urinary incontinence in women</p><p><em>Reproductive system and breast disorders</em></p><p>Uncommon: Erectile dysfunction</p><p><em>General disorders and administration site conditions</em></p><p>Very common: Asthenia (fatigue)</p><p>Common: Pain</p><p><em>(c) Description</em>&nbsp;of&nbsp;<em>selected adverse reactions</em></p><p>Dizziness, syncope, headache and asthenia are usually mild and are more likely to occur at the beginning of treatment.</p><p><em>In patients with congestive heart failure, worsening cardiac failure and fluid retention may occur during up-titration of carvedilol dose (see section 4.4).</em></p><p>Cardiac failure is a commonly reported adverse event in both placebo and carvedilol-treated patients (14.5% and 15.4% respectively, in patients with left ventricular dysfunction following acute myocardial infarction).</p><p>Reversible deterioration of renal function has been observed with carvedilol therapy in chronic heart failure patients with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or underlying renal insufficiency (see section 4.4).</p><p><em>As a class, beta-adrenergic receptor blockers may cause latent diabetes to become manifest, manifest diabetes to be aggravated, and blood glucose counter-regulation to be inhibited.</em></p><p>Carvedilol may cause urinary incontinence in women which resolves upon discontinuation of the medication.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To report any side effect(s):</p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and signs</p><p>In the event of overdose, there may be severe hypotension, bradycardia, heart failure, cardiogenic shock and cardiac arrest. There may also be respiratory problems, bronchospasm, vomiting, disturbed consciousness and generalized seizures.</p><p>Treatment</p><p>In addition to general supportive treatment, the vital parameters must be monitored and corrected, if necessary, under intensive care conditions.</p><p>Atropine can be used for excessive bradycardia, while to support ventricular function intravenous glucagon, or sympathomimetics (dobutamine, isoprenaline) are recommended. If positive inotropic effect is required, phosphodiesterase inhibitors (PDE) should be considered. If peripheral vasodilation dominates the intoxication profile then norfenephrine or noradrenaline should be administered with continuous monitoring of the circulation. In the case of drug-resistant bradycardia, pacemaker therapy should be initiated.</p><p>For bronchospasm, &beta;-sympathomimetics (as aerosol or intravenous) should be given, or aminophylline may be administered intravenously by slow injection or infusion. In the event of seizures, slow intravenous injection of diazepam or clonazepam is recommended.</p><p>Carvedilol is highly protein-bound. Therefore, it cannot be eliminated by dialysis.</p><p>In cases of severe overdose with symptoms of shock, supportive treatment must be continued for a sufficiently long period, i.e. until the patient&#39;s condition has stabilised, as a prolongation of elimination half-life and redistribution of carvedilol from deeper compartments are to be expected.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Alpha and beta blocking agents..</p><p>ATC code: C07AG02</p><p>Carvedilol is a vasodilatory non-selective beta-blocker, which reduces the peripheral vascular resistance by selective alpha 1- receptor blockade and suppresses the renin-angiotensin system through non-selective beta-blockade. Plasma renin activity is reduced and fluid retention is rare.</p><p>Carvedilol has no intrinsic sympathomimetic activity (ISA). Like propranolol, it has membrane stabilising properties.</p><p>Carvedilol is a racemate of two stereoisomers. Both enantiomers were found to have alpha-adrenergic blocking activity in animal models. Non-selective beta<sub>1</sub>- and beta<sub>2</sub>- adrenoceptor blockade is attributed mainly to the S(-) enantiomer.</p><p>The antioxidant properties of carvedilol and its metabolites have been demonstrated in&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;animal studies and&nbsp;<em>in vitro</em>&nbsp;in a number of human cell types.</p><p>In hypertensive patients, a reduction in blood pressure is not associated with a concomitant increase in peripheral resistance, as observed with pure beta-blocking agents. Heart rate is slightly decreased. Stroke volume remains unchanged. Renal blood flow and renal function remain normal, as does peripheral blood flow, therefore, cold extremities, often observed with beta-blockers, are rarely seen. In hypertensive patients carvedilol increases the plasma norepinephrine concentration.</p><p>In prolonged treatment of patients with angina, carvedilol has been seen to have an anti-ischaemic effect and to alleviate pain. Haemodynamic studies demonstrated that carvedilol reduces ventricular pre- and after-load. In patients with left ventricular dysfunction or congestive heart failure, carvedilol has a favourable effect on haemodynamics and left ventricular ejection fraction and dimensions.</p><p>Carvedilol has no negative effect on the serum lipid profile or electrolytes. The ratio of HDL (high-density lipoproteins) and LDL (low-density lipoproteins) remains normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Carvedilol is rapidly absorbed after oral administration. In healthy subjects, maximum serum concentration is achieved approximately 1 hour after administration. The absolute bioavailability of carvedilol in humans is approximately 25%.</p><p>There is a linear relationship between dose and serum concentrations of carvedilol. Food intake did not affect the bioavailability or the maximum serum concentration, although the time needed to reach maximum serum concentration is prolonged.</p><p>Distribution</p><p>Carvedilol is highly lipophilic. The plasma protein binding is about 98 to 99%. The volume of distribution is approximately 2 l / kg and increases in patients with liver cirrhosis.</p><p>Metabolism</p><p>In humans and in animal species studied, carvedilol is extensively metabolized to several metabolites which are excreted primarily in bile. The first pass effect after oral administration is about 60-75%. The enterohepatic circulation of the parent substance was demonstrated in animals.</p><p>Carvedilol is extensively metabolized in the liver, glucuronidation being one of the main reactions. The demethylation and hydroxylation at the phenol ring produce 3 active metabolites with blocking activity of beta-adrenergic receptors.</p><p>According to preclinical studies, the beta-blocking activity of the metabolite 4 - hydroxyphenol is approximately 13 times higher than that of carvedilol. The three active metabolites have a weak vasodilating activity, compared with carvedilol. In humans, their concentrations are about 10 times lower than the parent substance. Two of the carbazole-hydroxy metabolites are extremely potent antioxidants, showing a potency 30-80 times that of carvedilol.</p><p>Elimination</p><p>The average half-life of elimination of carvedilol is approximately 6 hours. The plasma clearance is approximately 500-700 ml / min. Elimination is mainly via the bile, and excretion mainly via the faeces. A minor part is eliminated renally in the form of various metabolites.</p><p>Pharmacokinetics in Special Populations</p><p><u>Patients with renal impairment</u></p><p>In some of the hypertensive patients with moderate to severe renal impairment (creatinine clearance &lt; 30 ml/min), an increase in plasma carvedilol concentrations of approximately 40-50 % was seen compared to patients with normal renal function. Peak plasma concentrations in patients with renal insufficiency increased also by an average of 10-20 %. However, there was a large variation in the results. Since carvedilol is primarily excreted via the faeces, significant accumulation in patients with renal impairment is unlikely.</p><p>In patients with moderate to severe renal impairment there is no need to modify carvedilol dosage (see section 4.2).</p><p>Patients with liver failure</p><p>In patients with liver cirrhosis, the systemic availability of carvedilol is increased 80% due to reduced first pass effect. Therefore, carvedilol is contraindicated in patients with clinically manifest hepatic impairment (see section 4.3 Contraindications).</p><p>Use in elderly</p><p>Age had a statistically significant effect on pharmacokinetic parameters of carvedilol in hypertensive patients. A study in elderly hypertensive patients showed no difference between the adverse event profile of this group and younger patients. Another study involving elderly patients with coronary artery disease showed no difference in reported adverse reactions vs. those that were reported by younger patients.</p><p>Use in pediatrics</p><p>The available information on pharmacokinetics in subjects younger than 18 years is limited.</p><p>Diabetic patients</p><p>In hypertensive patients with type 2 diabetes was not observed effect of carvedilol on blood glucose (fasting or postprandial) and glycosylated haemoglobin A1, it was not necessary to change the dose of antidiabetic drugs.</p><p>In patients with type 2 diabetes, carvedilol had no statistically significant influence on the glucose tolerance test. In nondiabetic hypertensive patients with altered insulin sensitivity (Syndrome X), carvedilol increased insulin sensitivity. The same results were observed in hypertensive patients with type 2 diabetes.</p><p>Heart failure</p><p>In a study in 24 patients with heart failure, the clearance of R-and S-carvedilol was significantly lower than previously estimated in healthy volunteers. These results suggested that the pharmacokinetics of R-and S-carvedilol is significantly altered by heart failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carvedilol demonstrated no mutagenic or carcinogenic potential.</p><p>High doses of carvedilol impaired fertility and affected pregnancy in rats (increased resorptions). Decreased fetal weight and delayed skeletal development were also seen in rats. Embryotoxicity (increased post-implantation loss) occurred in rats and rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:661px"><tbody><tr><td style="vertical-align:top"><p>Lactose</p></td></tr><tr><td style="vertical-align:top"><p>Maize Starch</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystalline Cellulose (Avicel pH 102)</p></td></tr><tr><td style="vertical-align:top"><p>Low-Substituted Hydroxypropyl Cellulose</p></td></tr><tr><td style="vertical-align:top"><p>Colloidal Silicon Dioxide</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc</p></td></tr><tr><td style="vertical-align:top"><p>Iron Oxide Red</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:661px"><tbody><tr><td><p>Not applicable</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36Months/3Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:661px"><tbody><tr><td><p>Store below 25&deg;C</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:661px"><tbody><tr><td><p>Package size: 30 tablets</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No Special Disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant

Saudi Pharmaceutical Industries &
Medical Appliance Corporation

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>